- Home
- CALC vs HHS Comparison
CALC vs HHS Comparison
Compare CALC & HHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALC
- HHS
- Stock Information
- Founded
- CALC 2011
- HHS 1923
- Country
- CALC United States
- HHS United States
- Employees
- CALC N/A
- HHS N/A
- Industry
- CALC Biotechnology: Pharmaceutical Preparations
- HHS Advertising
- Sector
- CALC Health Care
- HHS Consumer Discretionary
- Exchange
- CALC Nasdaq
- HHS Nasdaq
- Market Cap
- CALC 20.9M
- HHS 37.0M
- IPO Year
- CALC N/A
- HHS N/A
- Fundamental
- Price
- CALC $1.56
- HHS $4.99
- Analyst Decision
- CALC Strong Buy
- HHS
- Analyst Count
- CALC 3
- HHS 0
- Target Price
- CALC $16.33
- HHS N/A
- AVG Volume (30 Days)
- CALC 22.3K
- HHS 23.6K
- Earning Date
- CALC 05-12-2025
- HHS 05-12-2025
- Dividend Yield
- CALC N/A
- HHS N/A
- EPS Growth
- CALC N/A
- HHS N/A
- EPS
- CALC N/A
- HHS N/A
- Revenue
- CALC N/A
- HHS $185,242,000.00
- Revenue This Year
- CALC N/A
- HHS $6.54
- Revenue Next Year
- CALC N/A
- HHS N/A
- P/E Ratio
- CALC N/A
- HHS N/A
- Revenue Growth
- CALC N/A
- HHS N/A
- 52 Week Low
- CALC $1.43
- HHS $4.27
- 52 Week High
- CALC $6.27
- HHS $8.87
- Technical
- Relative Strength Index (RSI)
- CALC 33.00
- HHS 60.12
- Support Level
- CALC $1.43
- HHS $4.30
- Resistance Level
- CALC $1.54
- HHS $4.80
- Average True Range (ATR)
- CALC 0.09
- HHS 0.33
- MACD
- CALC 0.01
- HHS 0.07
- Stochastic Oscillator
- CALC 37.50
- HHS 100.00
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.